Global Biosimilars and Biologics Market - 2025-2033
Biosimilars and Biologics Market Size
The global biosimilars and biologics market size reached US$ 531.45 Billion in 2024 and is expected to reach US$ 1,773.77 Billion by 2033, growing at a CAGR of 14.4% during the forecast period 2025-2033.
Biosimilars and Biologics Market Overview
The global demand for biosimilars and biologics is robust. It continues to grow, driven by the increasing prevalence of chronic diseases, aging populations, technological advancements, and efforts to make healthcare more affordable. For instance, by the end of 2024, the FDA approved a total of 71 biosimilars, including six follow-on biologicals that did not undergo the BLA 351K process for use in the US. These novel product launches are boosting the market growth by offering a huge number of biosimilars.
Biosimilars and Biologics Market Dynamics: Drivers & Restraints
Rising aging populations and chronic disease burden are significantly driving the biosimilars and biologics market growth
As populations age, the prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders increases. These conditions often require long-term, specialized treatments, and biosimilars and biologics offer targeted and effective therapies for many of these diseases. The high efficacy of biologics and biosimilars in treating complex chronic conditions creates strong demand as the global elderly population grows.
For instance, according to the World Health Organization, by 2030, 1 in 6 people in the world will be aged 60 years or over. At this time, the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world’s population of people aged 60 years and older will double (2.1 billion). The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million. This aging population drives up the demand for biologics as a primary treatment option, expanding the market size. At the same time, this demographic’s high treatment needs exert financial pressure on healthcare systems, leading to an increased emphasis on cost-saving alternatives, such as biosimilars, once the original biologics’ patents expire.
Regulatory challenges are hampering the market growth
Regulatory challenges pose significant barriers to the growth of the biosimilars and biologics markets. These challenges stem from complex approval processes, differing regulations across regions, and stringent requirements that can delay market entry and increase costs. Unlike generics, biosimilars are required to undergo rigorous clinical testing to demonstrate safety, efficacy, and biosimilarity to their reference biologics.
Regulatory bodies like the FDA and EMA demand comprehensive evidence, including analytical, animal, and clinical data, to ensure biosimilars are comparable to original biologics. This approval process can be lengthy and costly, often requiring several years to complete.
In the United States, the FDA’s Biologics Price Competition and Innovation Act (BPCIA) provides a pathway for biosimilar approval, but the process remains time-consuming and expensive. For instance, Sandoz’s Zarxio (filgrastim-sndz) took about four years from initial development to FDA approval as the first U.S.-approved biosimilar. These extended timelines can delay market entry, limit the availability of biosimilars, and discourage investment in biosimilar development due to high upfront costs.
Biosimilars and Biologics Market, Segment Analysis
The global biosimilars and biologics market is segmented based on type, application, and region.
Application:
The oncology segment is expected to hold 31.27% of the market share in 2024 in the biosimilars and biologics market
Biosimilars in oncology have gained acceptance because they undergo rigorous clinical trials to demonstrate equivalence to their reference biologics. Over time, physicians and patients have become more comfortable with biosimilars in oncology due to clinical evidence and supportive real-world data. Their integration into oncology treatment regimens has helped build confidence in their use, which, in turn, supports further growth.
Cancer biologics are often prohibitively expensive, posing a financial challenge for healthcare systems and patients. Biosimilars offer similar efficacy and safety at a fraction of the cost, allowing for more sustainable oncology care and expanding access to advanced cancer treatments. For instance, in July 2024, Zydus Lifesciences Ltd cleared that the Mexican regulatory authority has granted marketing approval for Mamitra, a Trastuzumab biosimilar used to treat various types of cancer.
Biosimilars and Biologics Market, Geographical Analysis
North America is expected to dominate the global biosimilars and biologics market with a 42.18% share in 2024
North America, especially the United States and Canada, has huge aging populations, leading to a higher prevalence of diseases such as cancer, cardiovascular conditions, and autoimmune diseases, all of which require biologics and biosimilars. This drives both the demand for biologics and the need for affordable alternatives like biosimilars.
For instance, according to the Population Reference Bureau, the number of Americans ages 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050 (a 47% increase). Additionally, according to the CDC, an estimated 129 million people in the US have at least 1 major chronic disease. The National Health Council indicates that autoimmune diseases affect approximately 50 million Americans. The increasing availability of biosimilars for various chronic diseases expands patient access and improves treatment outcomes, further driving the market growth in the region.
The U.S. Food and Drug Administration (FDA) has established a clear and streamlined regulatory pathway for the approval of biosimilars. This includes the Biologics Price Competition and Innovation Act (BPCIA), which facilitates the approval of biosimilars and helps shorten the timeline for market entry. For instance, in April 2025, Biocon Biologics Ltd announced that the U.S. Food and Drug Administration (U.S. FDA) approved Jobevne (bevacizumab-nwgd), a biosimilar of Bevacizumab for intravenous use. JOBEVNE, a recombinant humanized monoclonal antibody used to treat several different types of cancer, is a biosimilar to the reference product Avastin (bevacizumab). These FDA approvals are accelerating the North America market growth.
Biosimilars and Biologics Market Competitive Landscape
Top companies in the biosimilars and biologics market include Amgen Inc., Johnson & Johnson, Biogen Inc., Teva Pharmaceutical Industries Limited, Biocon Biologics Inc., Pfizer Inc., Celltrion, Inc., Samsung Bioepis, AbbVie Inc., Boehringer Ingelheim International GmbH, and among others. The emerging players in the market include Eli Lilly and Company, Sanofi S.A., Fresenius Kabi AG, Coherus BioSciences Inc., Alvotech S.A., Polpharma Biologics S.A., Formycon AG, and Hexal AG, among others.
Industry Trends
The global biosimilars and biologics market size reached US$ 531.45 Billion in 2024 and is expected to reach US$ 1,773.77 Billion by 2033, growing at a CAGR of 14.4% during the forecast period 2025-2033.
Biosimilars and Biologics Market Overview
The global demand for biosimilars and biologics is robust. It continues to grow, driven by the increasing prevalence of chronic diseases, aging populations, technological advancements, and efforts to make healthcare more affordable. For instance, by the end of 2024, the FDA approved a total of 71 biosimilars, including six follow-on biologicals that did not undergo the BLA 351K process for use in the US. These novel product launches are boosting the market growth by offering a huge number of biosimilars.
Biosimilars and Biologics Market Dynamics: Drivers & Restraints
Rising aging populations and chronic disease burden are significantly driving the biosimilars and biologics market growth
As populations age, the prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders increases. These conditions often require long-term, specialized treatments, and biosimilars and biologics offer targeted and effective therapies for many of these diseases. The high efficacy of biologics and biosimilars in treating complex chronic conditions creates strong demand as the global elderly population grows.
For instance, according to the World Health Organization, by 2030, 1 in 6 people in the world will be aged 60 years or over. At this time, the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world’s population of people aged 60 years and older will double (2.1 billion). The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million. This aging population drives up the demand for biologics as a primary treatment option, expanding the market size. At the same time, this demographic’s high treatment needs exert financial pressure on healthcare systems, leading to an increased emphasis on cost-saving alternatives, such as biosimilars, once the original biologics’ patents expire.
Regulatory challenges are hampering the market growth
Regulatory challenges pose significant barriers to the growth of the biosimilars and biologics markets. These challenges stem from complex approval processes, differing regulations across regions, and stringent requirements that can delay market entry and increase costs. Unlike generics, biosimilars are required to undergo rigorous clinical testing to demonstrate safety, efficacy, and biosimilarity to their reference biologics.
Regulatory bodies like the FDA and EMA demand comprehensive evidence, including analytical, animal, and clinical data, to ensure biosimilars are comparable to original biologics. This approval process can be lengthy and costly, often requiring several years to complete.
In the United States, the FDA’s Biologics Price Competition and Innovation Act (BPCIA) provides a pathway for biosimilar approval, but the process remains time-consuming and expensive. For instance, Sandoz’s Zarxio (filgrastim-sndz) took about four years from initial development to FDA approval as the first U.S.-approved biosimilar. These extended timelines can delay market entry, limit the availability of biosimilars, and discourage investment in biosimilar development due to high upfront costs.
Biosimilars and Biologics Market, Segment Analysis
The global biosimilars and biologics market is segmented based on type, application, and region.
Application:
The oncology segment is expected to hold 31.27% of the market share in 2024 in the biosimilars and biologics market
Biosimilars in oncology have gained acceptance because they undergo rigorous clinical trials to demonstrate equivalence to their reference biologics. Over time, physicians and patients have become more comfortable with biosimilars in oncology due to clinical evidence and supportive real-world data. Their integration into oncology treatment regimens has helped build confidence in their use, which, in turn, supports further growth.
Cancer biologics are often prohibitively expensive, posing a financial challenge for healthcare systems and patients. Biosimilars offer similar efficacy and safety at a fraction of the cost, allowing for more sustainable oncology care and expanding access to advanced cancer treatments. For instance, in July 2024, Zydus Lifesciences Ltd cleared that the Mexican regulatory authority has granted marketing approval for Mamitra, a Trastuzumab biosimilar used to treat various types of cancer.
Biosimilars and Biologics Market, Geographical Analysis
North America is expected to dominate the global biosimilars and biologics market with a 42.18% share in 2024
North America, especially the United States and Canada, has huge aging populations, leading to a higher prevalence of diseases such as cancer, cardiovascular conditions, and autoimmune diseases, all of which require biologics and biosimilars. This drives both the demand for biologics and the need for affordable alternatives like biosimilars.
For instance, according to the Population Reference Bureau, the number of Americans ages 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050 (a 47% increase). Additionally, according to the CDC, an estimated 129 million people in the US have at least 1 major chronic disease. The National Health Council indicates that autoimmune diseases affect approximately 50 million Americans. The increasing availability of biosimilars for various chronic diseases expands patient access and improves treatment outcomes, further driving the market growth in the region.
The U.S. Food and Drug Administration (FDA) has established a clear and streamlined regulatory pathway for the approval of biosimilars. This includes the Biologics Price Competition and Innovation Act (BPCIA), which facilitates the approval of biosimilars and helps shorten the timeline for market entry. For instance, in April 2025, Biocon Biologics Ltd announced that the U.S. Food and Drug Administration (U.S. FDA) approved Jobevne (bevacizumab-nwgd), a biosimilar of Bevacizumab for intravenous use. JOBEVNE, a recombinant humanized monoclonal antibody used to treat several different types of cancer, is a biosimilar to the reference product Avastin (bevacizumab). These FDA approvals are accelerating the North America market growth.
Biosimilars and Biologics Market Competitive Landscape
Top companies in the biosimilars and biologics market include Amgen Inc., Johnson & Johnson, Biogen Inc., Teva Pharmaceutical Industries Limited, Biocon Biologics Inc., Pfizer Inc., Celltrion, Inc., Samsung Bioepis, AbbVie Inc., Boehringer Ingelheim International GmbH, and among others. The emerging players in the market include Eli Lilly and Company, Sanofi S.A., Fresenius Kabi AG, Coherus BioSciences Inc., Alvotech S.A., Polpharma Biologics S.A., Formycon AG, and Hexal AG, among others.
Industry Trends
- In March 2025, Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) of its operating company, Fresenius Kabi, had been approved by the U.S. Food and Drug Administration (FDA). These denosumab biosimilars are approved for all indications of the reference products: Prolia (denosumab) and Xgeva (denosumab), respectively.
- In March 2025, Celltrion announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO (omalizumab-igec) as the first and only biosimilar designated as interchangeable with XOLAIR (omalizumab) for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), Immunoglobulin E (IgE)-mediated food allergy, and chronic spontaneous urticaria (CSU).
- In March 2025, Celltrion announced that the U.S. Food and Drug Administration (FDA) approved STOBOCLO (CT-P41, denosumab-bmwo) and OSENVELT (CT-P41, denosumab-bmwo), biosimilars referencing PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of reference products.
- In February 2025, Samsung Bioepis Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for OSPOMYV (denosumab-dssb; SB16; 60 mg pre-filled syringe) and XBRYK (denosumab-dssb; SB16; 120 mg vial), biosimilars referencing Prolia and Xgeva, respectively.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Type
2.4. Snippet by Application
2.5. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Aging Populations and Chronic Disease Burden
3.1.1.2. Growing Demand for Biologics and Biosimilars
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Regulatory Challenges
3.1.2.2. XX
3.1.3. Opportunity
3.1.3.1. Expansion into Various Therapeutic Areas
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Patent Analysis
4.6. SWOT Analysis
4.7. Unmet Needs and Gaps
4.8. Recommended Strategies for Market Entry and Expansion
4.9. Pricing Analysis and Price Dynamics
5. BIOSIMILARS AND BIOLOGICS MARKET, BY TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
5.1.2. Market Attractiveness Index, By Type
5.2. Biologics*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.2.3. Monoclonal Antibodies
5.2.4. Vaccines
5.2.5. Recombinant Proteins
5.2.6. Blood Factors
5.2.7. Others
5.3. Biosimilars
5.3.1. Biosimilar Monoclonal Antibodies
5.3.2. Biosimilar Vaccines
5.3.3. Biosimilar Recombinant Proteins
5.3.4. Biosimilar Blood Factors
5.3.5. Others
6. BIOSIMILARS AND BIOLOGICS MARKET, BY APPLICATION
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
6.1.2. Market Attractiveness Index, By Application
6.2. Oncology*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Autoimmune Diseases
6.4. Chronic Diseases
6.5. Infectious Diseases
6.6. Neurology
6.7. Ophthalmology
6.8. Others
7. BIOSIMILARS AND BIOLOGICS MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
7.1.2. Market Attractiveness Index, By Region
7.2. North America
7.2.1. Introduction
7.2.2. Key Region-Specific Dynamics
7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.2.5.1. U.S.
7.2.5.2. Canada
7.2.5.3. Mexico
7.3. Europe
7.3.1. Introduction
7.3.2. Key Region-Specific Dynamics
7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.3.5.1. Germany
7.3.5.2. UK
7.3.5.3. France
7.3.5.4. Spain
7.3.5.5. Italy
7.3.5.6. Rest of Europe
7.4. Asia-Pacific
7.4.1. Introduction
7.4.2. Key Region-Specific Dynamics
7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.4.5.1. China
7.4.5.2. India
7.4.5.3. Japan
7.4.5.4. South Korea
7.4.5.5. Rest of Asia-Pacific
7.5. South America
7.5.1. Introduction
7.5.2. Key Region-Specific Dynamics
7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.5.5.1. Brazil
7.5.5.2. Argentina
7.5.5.3. Rest of South America
7.6. Middle East and Africa
7.6.1. Introduction
7.6.2. Key Region-Specific Dynamics
7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
8.1. Competitive Overview and Key Market Players
8.2. Market Share Analysis and Positioning Matrix
8.3. Strategic Partnerships, Mergers & Acquisitions
8.4. Key Developments in Product Portfolios and Innovations
8.5. Company Benchmarking
9. COMPANY PROFILES
9.1. Amgen Inc.*
9.1.1. Company Overview
9.1.2. Product Portfolio
9.1.2.1. Product Description
9.1.2.2. Product Key Performance Indicators (KPIs)
9.1.2.3. Historic and Forecasted Product Sales
9.1.3. Financial Overview
9.1.3.1. Company Revenue
9.1.3.2. Geographical Revenue Shares
9.1.3.3. Revenue Forecasts
9.1.4. Key Developments
9.1.4.1. Mergers & Acquisitions
9.1.4.2. Key Product Development Activities
9.1.4.3. Regulatory Approvals, etc.
9.1.5. SWOT Analysis
9.2. Johnson & Johnson
9.3. Biogen Inc.
9.4. Teva Pharmaceutical Industries Limited
9.5. Biocon Biologics Inc.
9.6. Pfizer Inc.
9.7. Celltrion, Inc.
9.8. Samsung Bioepis
9.9. AbbVie Inc.
9.10. Boehringer Ingelheim International GmbH
LIST NOT EXHAUSTIVE
10. ASSUMPTION AND RESEARCH METHODOLOGY
10.1. Data Collection Methods
10.2. Data Triangulation
10.3. Forecasting Techniques
10.4. Data Verification and Validation
11. APPENDIX
11.1. About Us and Services
11.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Type
2.4. Snippet by Application
2.5. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Aging Populations and Chronic Disease Burden
3.1.1.2. Growing Demand for Biologics and Biosimilars
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Regulatory Challenges
3.1.2.2. XX
3.1.3. Opportunity
3.1.3.1. Expansion into Various Therapeutic Areas
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Patent Analysis
4.6. SWOT Analysis
4.7. Unmet Needs and Gaps
4.8. Recommended Strategies for Market Entry and Expansion
4.9. Pricing Analysis and Price Dynamics
5. BIOSIMILARS AND BIOLOGICS MARKET, BY TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
5.1.2. Market Attractiveness Index, By Type
5.2. Biologics*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.2.3. Monoclonal Antibodies
5.2.4. Vaccines
5.2.5. Recombinant Proteins
5.2.6. Blood Factors
5.2.7. Others
5.3. Biosimilars
5.3.1. Biosimilar Monoclonal Antibodies
5.3.2. Biosimilar Vaccines
5.3.3. Biosimilar Recombinant Proteins
5.3.4. Biosimilar Blood Factors
5.3.5. Others
6. BIOSIMILARS AND BIOLOGICS MARKET, BY APPLICATION
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
6.1.2. Market Attractiveness Index, By Application
6.2. Oncology*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Autoimmune Diseases
6.4. Chronic Diseases
6.5. Infectious Diseases
6.6. Neurology
6.7. Ophthalmology
6.8. Others
7. BIOSIMILARS AND BIOLOGICS MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
7.1.2. Market Attractiveness Index, By Region
7.2. North America
7.2.1. Introduction
7.2.2. Key Region-Specific Dynamics
7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.2.5.1. U.S.
7.2.5.2. Canada
7.2.5.3. Mexico
7.3. Europe
7.3.1. Introduction
7.3.2. Key Region-Specific Dynamics
7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.3.5.1. Germany
7.3.5.2. UK
7.3.5.3. France
7.3.5.4. Spain
7.3.5.5. Italy
7.3.5.6. Rest of Europe
7.4. Asia-Pacific
7.4.1. Introduction
7.4.2. Key Region-Specific Dynamics
7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.4.5.1. China
7.4.5.2. India
7.4.5.3. Japan
7.4.5.4. South Korea
7.4.5.5. Rest of Asia-Pacific
7.5. South America
7.5.1. Introduction
7.5.2. Key Region-Specific Dynamics
7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.5.5.1. Brazil
7.5.5.2. Argentina
7.5.5.3. Rest of South America
7.6. Middle East and Africa
7.6.1. Introduction
7.6.2. Key Region-Specific Dynamics
7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
8.1. Competitive Overview and Key Market Players
8.2. Market Share Analysis and Positioning Matrix
8.3. Strategic Partnerships, Mergers & Acquisitions
8.4. Key Developments in Product Portfolios and Innovations
8.5. Company Benchmarking
9. COMPANY PROFILES
9.1. Amgen Inc.*
9.1.1. Company Overview
9.1.2. Product Portfolio
9.1.2.1. Product Description
9.1.2.2. Product Key Performance Indicators (KPIs)
9.1.2.3. Historic and Forecasted Product Sales
9.1.3. Financial Overview
9.1.3.1. Company Revenue
9.1.3.2. Geographical Revenue Shares
9.1.3.3. Revenue Forecasts
9.1.4. Key Developments
9.1.4.1. Mergers & Acquisitions
9.1.4.2. Key Product Development Activities
9.1.4.3. Regulatory Approvals, etc.
9.1.5. SWOT Analysis
9.2. Johnson & Johnson
9.3. Biogen Inc.
9.4. Teva Pharmaceutical Industries Limited
9.5. Biocon Biologics Inc.
9.6. Pfizer Inc.
9.7. Celltrion, Inc.
9.8. Samsung Bioepis
9.9. AbbVie Inc.
9.10. Boehringer Ingelheim International GmbH
LIST NOT EXHAUSTIVE
10. ASSUMPTION AND RESEARCH METHODOLOGY
10.1. Data Collection Methods
10.2. Data Triangulation
10.3. Forecasting Techniques
10.4. Data Verification and Validation
11. APPENDIX
11.1. About Us and Services
11.2. Contact Us
LIST OF TABLES
Table 1 Global Biosimilars and Biologics Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Biosimilars and Biologics Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Biosimilars and Biologics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Biosimilars and Biologics Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Biosimilars and Biologics Market Value, By Type, 2022-2033 (US$ Billion)
Table 6 Global Biosimilars and Biologics Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Biosimilars and Biologics Market Value, By Application, 2022-2033 (US$ Billion)
Table 8 Global Biosimilars and Biologics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Biosimilars and Biologics Market Value, By Region, 2022-2033 (US$ Billion)
Table 10 North America Biosimilars and Biologics Market Value, By Type, 2022-2033 (US$ Billion)
Table 11 North America Biosimilars and Biologics Market Value, By Application, 2022-2033 (US$ Billion)
Table 12 North America Biosimilars and Biologics Market Value, By Country, 2022-2033 (US$ Billion)
Table 13 Europe Biosimilars and Biologics Market Value, By Type, 2022-2033 (US$ Billion)
Table 14 Europe Biosimilars and Biologics Market Value, By Application, 2022-2033 (US$ Billion)
Table 15 Europe Biosimilars and Biologics Market Value, By Country, 2022-2033 (US$ Billion)
Table 16 Asia-Pacific Biosimilars and Biologics Market Value, By Type, 2022-2033 (US$ Billion)
Table 17 Asia-Pacific Biosimilars and Biologics Market Value, By Application, 2022-2033 (US$ Billion)
Table 18 Asia-Pacific Biosimilars and Biologics Market Value, By Country, 2022-2033 (US$ Billion)
Table 19 South America Biosimilars and Biologics Market Value, By Type, 2022-2033 (US$ Billion)
Table 20 South America Biosimilars and Biologics Market Value, By Application, 2022-2033 (US$ Billion)
Table 21 South America Biosimilars and Biologics Market Value, By Country, 2022-2033 (US$ Billion)
Table 22 Middle East and Africa Biosimilars and Biologics Market Value, By Type, 2022-2033 (US$ Billion)
Table 23 Middle East and Africa Biosimilars and Biologics Market Value, By Application, 2022-2033 (US$ Billion)
Table 24 Middle East and Africa Biosimilars and Biologics Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 Amgen Inc.: Overview
Table 26 Amgen Inc.: Product Portfolio
Table 27 Amgen Inc.: Key Developments
Table 28 Johnson & Johnson: Overview
Table 29 Johnson & Johnson: Product Portfolio
Table 30 Johnson & Johnson: Key Developments
Table 31 Biogen Inc.: Overview
Table 32 Biogen Inc.: Product Portfolio
Table 33 Biogen Inc.: Key Developments
Table 34 Teva Pharmaceutical Industries Limited: Overview
Table 35 Teva Pharmaceutical Industries Limited: Product Portfolio
Table 36 Teva Pharmaceutical Industries Limited: Key Developments
Table 37 Biocon Biologics Inc.: Overview
Table 38 Biocon Biologics Inc.: Product Portfolio
Table 39 Biocon Biologics Inc.: Key Developments
Table 40 Pfizer Inc.: Overview
Table 41 Pfizer Inc.: Product Portfolio
Table 42 Pfizer Inc.: Key Developments
Table 43 Celltrion, Inc.: Overview
Table 44 Celltrion, Inc.: Product Portfolio
Table 45 Celltrion, Inc.: Key Developments
Table 46 Samsung Bioepis: Overview
Table 47 Samsung Bioepis: Product Portfolio
Table 48 Samsung Bioepis: Key Developments
Table 49 AbbVie Inc.: Overview
Table 50 AbbVie Inc.: Product Portfolio
Table 51 AbbVie Inc.: Key Developments
Table 52 Boehringer Ingelheim International GmbH: Overview
Table 53 Boehringer Ingelheim International GmbH: Product Portfolio
Table 54 Boehringer Ingelheim International GmbH: Key Developments
Table 1 Global Biosimilars and Biologics Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Biosimilars and Biologics Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Biosimilars and Biologics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Biosimilars and Biologics Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Biosimilars and Biologics Market Value, By Type, 2022-2033 (US$ Billion)
Table 6 Global Biosimilars and Biologics Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Biosimilars and Biologics Market Value, By Application, 2022-2033 (US$ Billion)
Table 8 Global Biosimilars and Biologics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Biosimilars and Biologics Market Value, By Region, 2022-2033 (US$ Billion)
Table 10 North America Biosimilars and Biologics Market Value, By Type, 2022-2033 (US$ Billion)
Table 11 North America Biosimilars and Biologics Market Value, By Application, 2022-2033 (US$ Billion)
Table 12 North America Biosimilars and Biologics Market Value, By Country, 2022-2033 (US$ Billion)
Table 13 Europe Biosimilars and Biologics Market Value, By Type, 2022-2033 (US$ Billion)
Table 14 Europe Biosimilars and Biologics Market Value, By Application, 2022-2033 (US$ Billion)
Table 15 Europe Biosimilars and Biologics Market Value, By Country, 2022-2033 (US$ Billion)
Table 16 Asia-Pacific Biosimilars and Biologics Market Value, By Type, 2022-2033 (US$ Billion)
Table 17 Asia-Pacific Biosimilars and Biologics Market Value, By Application, 2022-2033 (US$ Billion)
Table 18 Asia-Pacific Biosimilars and Biologics Market Value, By Country, 2022-2033 (US$ Billion)
Table 19 South America Biosimilars and Biologics Market Value, By Type, 2022-2033 (US$ Billion)
Table 20 South America Biosimilars and Biologics Market Value, By Application, 2022-2033 (US$ Billion)
Table 21 South America Biosimilars and Biologics Market Value, By Country, 2022-2033 (US$ Billion)
Table 22 Middle East and Africa Biosimilars and Biologics Market Value, By Type, 2022-2033 (US$ Billion)
Table 23 Middle East and Africa Biosimilars and Biologics Market Value, By Application, 2022-2033 (US$ Billion)
Table 24 Middle East and Africa Biosimilars and Biologics Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 Amgen Inc.: Overview
Table 26 Amgen Inc.: Product Portfolio
Table 27 Amgen Inc.: Key Developments
Table 28 Johnson & Johnson: Overview
Table 29 Johnson & Johnson: Product Portfolio
Table 30 Johnson & Johnson: Key Developments
Table 31 Biogen Inc.: Overview
Table 32 Biogen Inc.: Product Portfolio
Table 33 Biogen Inc.: Key Developments
Table 34 Teva Pharmaceutical Industries Limited: Overview
Table 35 Teva Pharmaceutical Industries Limited: Product Portfolio
Table 36 Teva Pharmaceutical Industries Limited: Key Developments
Table 37 Biocon Biologics Inc.: Overview
Table 38 Biocon Biologics Inc.: Product Portfolio
Table 39 Biocon Biologics Inc.: Key Developments
Table 40 Pfizer Inc.: Overview
Table 41 Pfizer Inc.: Product Portfolio
Table 42 Pfizer Inc.: Key Developments
Table 43 Celltrion, Inc.: Overview
Table 44 Celltrion, Inc.: Product Portfolio
Table 45 Celltrion, Inc.: Key Developments
Table 46 Samsung Bioepis: Overview
Table 47 Samsung Bioepis: Product Portfolio
Table 48 Samsung Bioepis: Key Developments
Table 49 AbbVie Inc.: Overview
Table 50 AbbVie Inc.: Product Portfolio
Table 51 AbbVie Inc.: Key Developments
Table 52 Boehringer Ingelheim International GmbH: Overview
Table 53 Boehringer Ingelheim International GmbH: Product Portfolio
Table 54 Boehringer Ingelheim International GmbH: Key Developments
LIST OF FIGURES
Figure 1 Global Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Biosimilars and Biologics Market Share, By Type, 2024 & 2033 (%)
Figure 3 Global Biosimilars and Biologics Market Share, By Application, 2024 & 2033 (%)
Figure 4 Global Biosimilars and Biologics Market Share, By Region, 2024 & 2033 (%)
Figure 5 Global Biosimilars and Biologics Market Y-o-Y Growth, By Type, 2023-2033 (%)
Figure 6 Biologics Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 7 Biosimilars Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 8 Global Biosimilars and Biologics Market Y-o-Y Growth, By Application, 2023-2033 (%)
Figure 9 Oncology Application in Global Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 10 Autoimmune Diseases Application in Global Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 11 Chronic Diseases Application in Global Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 12 Infectious Diseases Application in Global Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 13 Neurology Application in Global Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 14 Ophthalmology Application in Global Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 15 Others Application in Global Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 16 Global Biosimilars and Biologics Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 17 North America Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 18 North America Biosimilars and Biologics Market Share, By Type, 2024 & 2033 (%)
Figure 19 North America Biosimilars and Biologics Market Share, By Application, 2024 & 2033 (%)
Figure 20 North America Biosimilars and Biologics Market Share, By Country, 2024 & 2033 (%)
Figure 21 Europe Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 22 Europe Biosimilars and Biologics Market Share, By Type, 2024 & 2033 (%)
Figure 23 Europe Biosimilars and Biologics Market Share, By Application, 2024 & 2033 (%)
Figure 24 Europe Biosimilars and Biologics Market Share, By Country, 2024 & 2033 (%)
Figure 25 Asia-Pacific Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 26 Asia-Pacific Biosimilars and Biologics Market Share, By Type, 2024 & 2033 (%)
Figure 27 Asia-Pacific Biosimilars and Biologics Market Share, By Application, 2024 & 2033 (%)
Figure 28 Asia-Pacific Biosimilars and Biologics Market Share, By Country, 2024 & 2033 (%)
Figure 29 South America Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 30 South America Biosimilars and Biologics Market Share, By Type, 2024 & 2033 (%)
Figure 31 South America Biosimilars and Biologics Market Share, By Application, 2024 & 2033 (%)
Figure 32 South America Biosimilars and Biologics Market Share, By Country, 2024 & 2033 (%)
Figure 33 Middle East and Africa Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 34 Middle East and Africa Biosimilars and Biologics Market Share, By Type, 2024 & 2033 (%)
Figure 35 Middle East and Africa Biosimilars and Biologics Market Share, By Application, 2024 & 2033 (%)
Figure 36 Amgen Inc.: Financials
Figure 37 Johnson & Johnson: Financials
Figure 38 Biogen Inc.: Financials
Figure 39 Teva Pharmaceutical Industries Limited: Financials
Figure 40 Biocon Biologics Inc.: Financials
Figure 41 Pfizer Inc.: Financials
Figure 42 Celltrion, Inc.: Financials
Figure 43 Samsung Bioepis: Financials
Figure 44 AbbVie Inc.: Financials
Figure 45 Boehringer Ingelheim International GmbH: Financials
Figure 1 Global Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Biosimilars and Biologics Market Share, By Type, 2024 & 2033 (%)
Figure 3 Global Biosimilars and Biologics Market Share, By Application, 2024 & 2033 (%)
Figure 4 Global Biosimilars and Biologics Market Share, By Region, 2024 & 2033 (%)
Figure 5 Global Biosimilars and Biologics Market Y-o-Y Growth, By Type, 2023-2033 (%)
Figure 6 Biologics Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 7 Biosimilars Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 8 Global Biosimilars and Biologics Market Y-o-Y Growth, By Application, 2023-2033 (%)
Figure 9 Oncology Application in Global Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 10 Autoimmune Diseases Application in Global Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 11 Chronic Diseases Application in Global Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 12 Infectious Diseases Application in Global Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 13 Neurology Application in Global Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 14 Ophthalmology Application in Global Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 15 Others Application in Global Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 16 Global Biosimilars and Biologics Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 17 North America Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 18 North America Biosimilars and Biologics Market Share, By Type, 2024 & 2033 (%)
Figure 19 North America Biosimilars and Biologics Market Share, By Application, 2024 & 2033 (%)
Figure 20 North America Biosimilars and Biologics Market Share, By Country, 2024 & 2033 (%)
Figure 21 Europe Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 22 Europe Biosimilars and Biologics Market Share, By Type, 2024 & 2033 (%)
Figure 23 Europe Biosimilars and Biologics Market Share, By Application, 2024 & 2033 (%)
Figure 24 Europe Biosimilars and Biologics Market Share, By Country, 2024 & 2033 (%)
Figure 25 Asia-Pacific Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 26 Asia-Pacific Biosimilars and Biologics Market Share, By Type, 2024 & 2033 (%)
Figure 27 Asia-Pacific Biosimilars and Biologics Market Share, By Application, 2024 & 2033 (%)
Figure 28 Asia-Pacific Biosimilars and Biologics Market Share, By Country, 2024 & 2033 (%)
Figure 29 South America Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 30 South America Biosimilars and Biologics Market Share, By Type, 2024 & 2033 (%)
Figure 31 South America Biosimilars and Biologics Market Share, By Application, 2024 & 2033 (%)
Figure 32 South America Biosimilars and Biologics Market Share, By Country, 2024 & 2033 (%)
Figure 33 Middle East and Africa Biosimilars and Biologics Market Value, 2022-2033 (US$ Billion)
Figure 34 Middle East and Africa Biosimilars and Biologics Market Share, By Type, 2024 & 2033 (%)
Figure 35 Middle East and Africa Biosimilars and Biologics Market Share, By Application, 2024 & 2033 (%)
Figure 36 Amgen Inc.: Financials
Figure 37 Johnson & Johnson: Financials
Figure 38 Biogen Inc.: Financials
Figure 39 Teva Pharmaceutical Industries Limited: Financials
Figure 40 Biocon Biologics Inc.: Financials
Figure 41 Pfizer Inc.: Financials
Figure 42 Celltrion, Inc.: Financials
Figure 43 Samsung Bioepis: Financials
Figure 44 AbbVie Inc.: Financials
Figure 45 Boehringer Ingelheim International GmbH: Financials
